FDG-PET and MRI in the Evolution of New-Onset Refractory Status Epilepticus
Overview
Authors
Affiliations
Background And Purpose: New-onset refractory status epilepticus is a clinical condition characterized by acute and prolonged pharmacoresistant seizures without a pre-existing relevant neurologic disorder, prior epilepsy, or clear structural, toxic, or metabolic cause. New-onset refractory status epilepticus is often associated with antineuronal antibodies and may respond to early immunosuppressive therapy, reflecting an inflammatory element of the condition. FDG-PET is a useful diagnostic tool in inflammatory and noninflammatory encephalitis. We report here FDG-PET findings in new-onset refractory status epilepticus and their correlation to disease activity, other imaging findings, and outcomes.
Materials And Methods: Twelve patients who met the criteria for new-onset refractory status epilepticus and who had FDG-PET and MR imaging scans and electroencephalography at a single academic medical center between 2008 and 2017 were retrospectively identified. Images were independently reviewed by 2 radiologists specialized in nuclear imaging. Clinical characteristics and outcome measures were collected through chart review.
Results: Twelve patients underwent 21 FDG-PET scans and 50 MR imaging scans. Nine (75%) patients were positive for autoantibodies. All patients had identifiable abnormalities on the initial FDG-PET in the form of hypermetabolism (83%) and/or hypometabolism (42%). Eight (67%) had medial temporal involvement. All patients ( = 3) with -methyl-D-aspartic acid receptor antibodies had profound bilateral occipital hypometabolism. Initial MR imaging findings were normal in 6 (50%) patients. Most patients had some degree of persistent hyper- (73%) or hypometabolism (45%) after immunosuppressive therapy. FDG-PET hypometabolism was predictive of poor outcome (mRS 4-6) at hospital discharge ( = .028).
Conclusions: Both FDG-PET hypometabolism and hypermetabolism are seen in the setting of new-onset refractory status epilepticus and may represent markers of disease activity.
Understanding new-onset refractory status epilepticus from an immunological point of view.
Shin Y Encephalitis. 2023; 1(3):61-67.
PMID: 37469848 PMC: 10295883. DOI: 10.47936/encephalitis.2021.00045.
Zhang C, Hao Y, Huang G, Xin M, Bai S, Guan Y CNS Neurosci Ther. 2023; 29(6):1624-1635.
PMID: 36815303 PMC: 10173717. DOI: 10.1111/cns.14125.
Inflammation as Treatment Target for Status Epilepticus.
Rejdak K, Pikulicka A, Piekarska M, Pacek K, Plachta K Curr Neuropharmacol. 2022; 21(3):708-714.
PMID: 36397618 PMC: 10207918. DOI: 10.2174/1570159X21666221117152249.
Kassab A, Toffa D, Robert M, Lesage F, Peng K, Nguyen D Neuroimage Clin. 2021; 32:102880.
PMID: 34773798 PMC: 8594770. DOI: 10.1016/j.nicl.2021.102880.
Bordonne M, Chawki M, Doyen M, Kas A, Guedj E, Tyvaert L Eur J Nucl Med Mol Imaging. 2021; 48(12):3847-3858.
PMID: 33677643 DOI: 10.1007/s00259-021-05299-y.